Seminars in Hematology
Volume 37, Issue 1 , Pages 3-14 , January 2000

Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia

  • Neal S Young

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Neal S. Young, MD, Bldg 10, Room 7C103, National Institutes of Health, Bethesda, MD 20892-1652.

References 

  1. Abkowitz JL, Linenberger ML, et al.  Evidence for the maintenance of hematopoiesis in a large animal by the sequential activation of stem-cell clones. In: ed 2. Proc Natl Acad Sci USA. 87:1990;p. 9062–9066
  2. Alter MJ, Gallagher M, Morris TT, et al.  Acute non-A-E hepatitis in me United States and the role of hepatitis G virus infection. N Engl J Med. 1997;336:741–746
  3. Anderson KC, Weinstein HJ. Transfusion-associated graft versus-host disease. N Engl J Med. 1990;323:315–321
  4. Aoki I, Higashi K, Homori M, et al.  Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome. Am J Hematol. 1990;35:6–12
  5. Araten D, Nafa K, Pakdeesuwan K, et al.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. In: ed 2. Proc Natl Acad Sci USA. 96:1999;p. 5209–5214
  6. Baciagalupo A, Piaggio G, Figari O, et al.  Response of CFU-GM to increasing doses of rhGM-CSF in patients with aplastic anemia. Exp Hematol. 1991;19:829–832
  7. Bacigalupo A, Podesta M, Frassoni F, et al.  Generation of CFU-C suppressor T cells in vitro V. A multistep process. Br J Haematol. 1982;52:421–427
  8. Bacigalupo A. Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression. Eur J Haematol. 1996;57(suppl 60):16–19
  9. Ball SE, Gibson FM, Rizzo S, et al.  Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582–3592
  10. Binder D, van den Broek M, Kagi D, et al.  Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med. 1998;187:1903–1920
  11. Birk OS, Gur SL, Elias D, et al.  The 60-kDa heat shock protein modulates allograft rejection. In: ed 2. Proc Natl Acad Sci USA. 96:1999;p. 5159–5163
  12. Brown KE, Tisdale J, Dunbar CE, et al.  Hepatitis-associated aplastic anemia. N Engl J Med. 1997;336:1059–1064
  13. Cahill DP, Lengauer C, Yu J, et al.  Mutations of mitotic checkpoint genes in human cancers. Nature. 1998;392:300–303
  14. Chapuis B, Von Fliedner VE, Jeannet M, et al.  Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol. 1986;63:51–57
  15. Corwin AL, Dai TC, Duc DD, et al.  Acute viral hepatitis in Hanoi, Viet Nam. Trans R Soc Trop Med Hyg. 1996;90:647–648
  16. Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol. 1997;159:3–6
  17. Devetten MP, Young NS. Hematopoietic growth factors in the pathophysiology and treatment of aplastic anemia. In:  Hoelzer D,  Ganser A editor. Cytokines in the Treatment of Hematopoietic Failure. New York, NY: Marcel Dekker; 1998;p. 155–169
  18. Dunn DE, Tannawattanacharoen P, Boccuni P, et al.  Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401–408
  19. Dunn DE, Yu J, Nagarajan S, et al.  A knock-out model of paroxysmal nocturnal hemoglobinuria: PIG-A-hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins. In: ed 2. Proc Natl Acad Sci USA. 93:1996;p. 7938–7943
  20. Ehl S, Hombach J, Aichele P, et al.  Bystander activation of cytotoxic T cells: Studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med. 1997;185:1241–1251
  21. Fleischhauer K, Kernan NA, O'Reilly RJ, et al.  Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med. 1990;323:1818–1822
  22. Gale RE, Wainscoat JS. Clonal analysis using X-linked DNA polymorphisms. Br J Haematol. 1993;85:2–8
  23. Gascon P, Zoumbos N, Young NS. An analysis of natural killer cells in aplastic anemia. Blood. 1986;67:1349–1355
  24. Gerson WT, Fine DG, Spielberg SP, et al.  Anticonvulsant-induced aplastic anemia: Increased susceptibility to toxic drug metabolites in vitro. Blood. 1983;61:889–893
  25. Hertenstein B, Wagner B, Bunjes D, et al.  Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995;86:1487–1492
  26. Ito K, Yoshida H, Yanagibashi K, et al.  Change of HLA phenotype in postoperative erythroderma. Lancet. 1988;1:413–414
  27. Jonasova A, Neuwirtova R, Cermak J, et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;200:304–309
  28. Kagan WA, Ascensao JA, Pahwa RN, et al.  Aplastic anemia: Presence in human bone marrow of cells that suppress myelopoiesis. In: ed 2. Proc Natl Acad Sci USA. 73:1976;p. 2890–2894
  29. Kawagoe K, Kitamura D, Okabe M, et al.  Glycosylphosphatidylinositol-anchor-deficient mice: Implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:3600–3606
  30. Kearns WG, Liu J, Aridgides L, et al.  Genomic instability in bone marrow failure syndromes: High frequency of aneuploidy by fluorescence in situ hybridization and identification of a spindle checkpoint gene mutation. Blood. 1999;(suppl 1): abstr (in press)
  31. Kelton HG, Huang AT, Mold N, et al.  The use of in vitro technics to study drug-induced pancytopenia. N Engl J Med. 1979;301:621–624
  32. Kim S-C, Min Y-H, Lee S, et al.  Delayed activation-induced T lymphocytes death in aplastic anemia: Related with abnormal Fas system. Korean J Intern Med. 1998;13:41–46
  33. Koijima S. Hematopoietic growth factors and marrow stroma in aplastic anemia. Int J Hematol. 1998;68:19–28
  34. Kojima S, Matsuyama T, Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia. Br J Haematol. 1997;99:440–446
  35. Laver J, Castro-Malaspina H, Kernan NA, et al.  In vitro interferon-gamma production by cultured T-cells in severe aplastic anaemia: Correlation with granulomonopoietic inhibition in patients who respond to anti-thymocyte globulin. Br J Haematol. 1988;69:545–550
  36. Lehmann PV, Forsthuber T, Miller A, et al.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992;358:155–157
  37. Li S, Champlin R, Fitchen JH, et al.  Abnormalities of myeloid progenitor cells after “successful” bone marrow transplantation. J Clin Invest. 1985;75:234–241
  38. Lieberman JA, Yunis J, Egea E, et al.  HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990;47:945–948
  39. Locasciulli A, Broccia G, Corda G, et al.  Risk of cytogenetic abnormalities in patients with severe aplastic anemia receiving immunosuppression with or without G-CSF. Bone Marrow Transplant. 1999;23(suppl 1):S30; abstr
  40. Lyman SD, Seaberg M, Hanna R, et al.  Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood. 1995;86:4091–4096
  41. Maciejewski JP, Anderson S, Katevas P, et al.  Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol. 1994;87:227–234
  42. Maciejewski JP, Hibbs JR, Anderson S, et al.  Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol. 1994;22:1102–1110
  43. Maciejewski JP, Selleri C, Sato T, et al.  Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. Br J Haematol. 1995;91:245–252
  44. Maciejewski JP, Selleri C, Sato T, et al.  A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88:1983–1991
  45. Maciejewski JP, Selleri C, Sato T, et al.  Nitric oxide suppression of human hematopoiesis in vitro: Contribution to inhibitory action of interferon-α and tumor necrosis factor-α. J Clin Invest. 1995;96:1085–1092
  46. Maciejewski JP, Sloand EM, Sato T, et al.  Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood. 1997;89:1173–1181
  47. Manz CY, Dietrich PY, Schnuriger Y, et al.  T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. Blood Cells Mol Dis. 1997;23:110–122
  48. Manz CY, Nissen C, Wodnar-Fillipowicz A. Deficiency of CD34+ c-kit+ and CD34+38− hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Am J Hematol. 1996;52:264–274
  49. Marsh JCW, Chang J, Testa NG, et al.  In vitro assesssment of marrow ‘stem cell’ and stromal cell function in aplastic anaemia. Br J Haematol. 1991;78:258–267
  50. Mathé G, Amiel JL, Schwarzenberg L, et al.  Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2:131–136
  51. Maulopoulos L, Dimopoulos M. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood. 1997;90:2127–2147
  52. McGuire W, Knight JC, Hill AV, et al.  Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis. 1999;179:287–290
  53. McManus PM, Weiss L. Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies. Blood. 1984;64:1036–1041
  54. Melenhorst JJ, van Krieken JHJM, Dreef E, et al.  T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia. Br J Haematol. 1997;99:517–519
  55. Moebius U, Hermann F, Hercend T, et al.  Clonal analysis of T cells in a patient with aplastic anemia. J Clin Invest. 1991;87:1567–1574
  56. Molldrem J, Caples M, Mavroudis D, et al.  Antithymocyte globulin (ATG) abrogates cytopenias in patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699–705
  57. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998;102:1314–1322
  58. Mori T, Nishimura T, Ikeda Y, et al.  Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression. Blood. 1998;92:101–107
  59. Myint AA, Malkovska V, Morgan S, et al.  Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anemia. Br J Haematol. 1990;75:578–584
  60. Nakamoto Y, Guidotti LG, Kuhlen CV, et al.  Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998;188:341–350
  61. Nakao S, Takamatsu H, Chuhjo T, et al.  Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257–4261
  62. Nakao S, Takamatsu H, Yachie A, et al.  Establishment of a CD4+ T cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia. Exp Hematol. 1995;23:433–438
  63. Nakao S, Takami A, Takamatsu H, et al.  Isolation of aT-cell clone showing HLA-DRB1 0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood. 1997;89:3691–3699
  64. Nakao S, Yamaguchi M, Shiobara S. Interferon gamma gene expression in unstimulated bone marrow mononuclear cells predicts a response to cyclosporine therapy in aplastic anemia. Blood. 1992;79:2532–2535
  65. Nguyen T, Brunson D, Crespi CL, et al.  DNA damage and mutation in human cells exposed to nitric oxide in vitro. In: ed 2. Proc Natl Acad Sci USA. 89:1992;p. 3030–3034
  66. Nimer SD, Ireland P, Meshkinpour A, et al.  An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 1994;84:923–927
  67. Nisticò A, Young NS. Gamma-interferon gene expression in the bone marrow of patients with acquired aplastic anemia. Ann Intern Med. 1994;120:463–469
  68. Notaro R, Cimmino A, Tabarini D, et al.  In vivo telomere dynamics of human hematopoietic stem cells. In: ed 2. Proc Natl Acad Sci USA. 94:1997;p. 13782–13785
  69. Novitzky N, Jacobs P. Immunosuppressive therapy in bone marrow aplasia: The stroma functions normally to support hematopoeisis. Exp Hematol. 1995;23:1472–1477
  70. Philpott NJ, Scopes J, Marsh JCW, et al.  Increased apoptosis in aplastic anemia bone marrow progenitor cells: Possible pathophysiologic significance. Exp Hematol. 1995;23:1642–1648
  71. Platanias L, Gascon P, Bielory L, et al.  Lymphocyte subsets and lymphokines following and-thymocyte globulin therapy in patients with aplastic anaemia. Br J Haematol. 1987;66:433–443
  72. 'Podesta M, Piaggio G, Frassoni F, et al.  The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91:1959–1965
  73. Raghavachar A, Janssen JWG, Schrezenmeier H, et al.  Clonal hematopoiesis as defined by polymorphic-X-linked loci occurs infrequendy in aplastic anemia. Blood. 1995;86:2938–2947
  74. Sato T, Selleri C, Young NS, et al.  Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3. Blood. 1997;90:4749–4758
  75. Schrezenmeier H, Jenal M, Herrmann F, et al.  Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood. 1996;88:4474–4480
  76. Selleri C, Maciejewski JP, Sato T, et al.  Interferon-gamma constitutively expressed in the stromal microenviroment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 1996;87:4149–4157
  77. Selleri C, Sato T, Anderson S, et al.  Interferon-γ and tumor necrosis factor-α suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165:538–546
  78. Shetty Y, Mundle S, Alvi S, et al.  Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20:891–900
  79. Sloand E, Maciejewski JP, Kim S, et al: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (in press)
  80. Stacey MW, Mcaninch T, Santi L, et al.  Glutathione-S transferase (GSTT1 and GSTM1) null genotypes in patients with aplastic anemia and myelodysplastic syndromes. Blood. 1999;(suppl 1): abstr (in press)
  81. Tamai H, Sudo T, Kimura A, et al.  Association between the DRB1∗08032 histocompatibilty antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann Intern Med. 1996;124:490–494
  82. Tong J, Bacigalupo A, Piaggio G, et al.  In vitro response of T cells from aplastic anemia patients to antilymphocyte globulin and phytohemagglutinin: Colony-stimulating activity and lymphokine production. Exp Hematol. 1991;19:312–316
  83. White JR, Josten KM, Chopra R, et al.  Absence of N-RAS point mutations in peripheral with aplastic anaemia and paroxysmal nocturnal haemoglobinurea. Br J Haematol. 1995;91:921–923
  84. Wolk A, Simon-Stoos K, Nami I, et al.  A mouse model of immune-mediated aplastic anemia. Blood. 1998;10(suppl 1):158a; abstr
  85. Yoshida K, Miura I, Takahashi T, et al.  Quantitative and qualitative analysis of stem cells of patients with aplastic anemia. Scand J Haematol. 1983;30:317–323
  86. Young NS. The problem of clonality in aplastic anemia. Dr. Dameshek's riddle, restated. Blood. 1992;79:1385–1392
  87. Young NS. Drugs and chemicals. In:  Young NS,  Alter BP editor. Aplastic Anemia, Acquired and Inherited. Philadelphia, PA: Saunders; 1994;p. 100
  88. Young NS: Agranulocytosis, in Young NS (ed): The Bone Marrow Failure Syndromes. Philadelphia, PA, Saunders (in press)
  89. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367–3377
  90. Zeng W, Nakano S, Takamatsu H, et al.  Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: Evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood. 1999;93:3008–3016
  91. Zoumbos N, Djeu J, Young N. Interferon is the suppressor of lymphocytes generated by stimulated lymphocytes in vitro. J Immunol. 1984;133:769–774
  92. Zoumbos N, Gascon P, Djeu J, et al.  Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. In: ed 2. Proc Natl Acad Sci USA. 82:1985;p. 188–192

☆ This is a US government work. There are no restrictions to its use.

PII: S0037-1963(00)90026-X

Seminars in Hematology
Volume 37, Issue 1 , Pages 3-14 , January 2000

Article Tools